12月2日 - ** 药物开发商Arrowhead Pharmaceuticals ARWR.O股价盘前上涨1%至57.23美元
** 该公司称美国食品及药物管理局授予其实验性药物plozasiran治疗严重高甘油三酯血症患者的突破性标签
** 高甘油三酯血症涉及极高的血脂水平，会增加急性胰腺炎的风险
** 公司的 plozasiran 旨在通过阻断 apoC-III（一种减缓脂肪分解的蛋白质）来降低血脂 - ARWR
** ARWR 计划在 2026 年中期完成后期试验
** 该公司预计在 2026 年底前申请美国食品和药物管理局的批准，并在晚些时候寻求全球批准
** 截至上次收盘，股价上涨 ~199
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.